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ABSTRACT
Background Despite growing interest, there is no 
guidance or consensus on how to conduct clinical trials 
and observational studies in populations at risk of 
rheumatoid arthritis (RA).
Methods An European League Against Rheumatism 
(EULAR) task force formulated four research questions 
to be addressed by systematic literature review (SLR). 
The SLR results informed consensus statements. One 
overarching principle, 10 points to consider (PTC) and 
a research agenda were proposed. Task force members 
rated their level of agreement (1–10) for each PTC.
Results Epidemiological and demographic 
characteristics should be measured in all clinical trials 
and studies in at- risk individuals. Different at- risk 
populations, identified according to clinical presentation, 
were defined: asymptomatic, musculoskeletal symptoms 
without arthritis and early clinical arthritis. Study end- 
points should include the development of subclinical 
inflammation on imaging, clinical arthritis, RA and 
subsequent achievement of arthritis remission. Risk 
factors should be assessed at baseline and re- evaluated 
where appropriate; they include genetic markers and 
autoantibody profiling and additionally clinical symptoms 
and subclinical inflammation on imaging in those with 
symptoms and/or clinical arthritis. Trials should address 
the effect of the intervention on risk factors, as well as 
progression to clinical arthritis or RA. In patients with 
early clinical arthritis, pharmacological intervention has 
the potential to prevent RA development. Participants’ 
knowledge of their RA risk may inform their decision 
to participate; information should be provided using an 
individually tailored approach.
Conclusion These consensus statements provide data- 
driven guidance for rheumatologists, health professionals 
and investigators conducting clinical trials and 
observational studies in individuals at risk of RA.
INTRODUCTION
It is now clear that the onset of rheumatoid arthritis 
(RA) is preceded by a complex preclinical phase.1 
While the early arthritis paradigm (ie, early identifi-
cation and treatment) has revolutionised the outlook 
of RA, interventions targeting the preclinical phase 
may unleash an even greater therapeutic leap. In 
the preclinical phase, ‘at- risk’ individuals, many 
of whom have genetic or environmental predispo-
sitions, develop autoantibodies and/or symptoms 
and eventually progress to clinical arthritis and 
classifiable RA.2 Over the last decade, longitudinal 
observational studies of prospective at- risk cohorts 
have identified risk factors and biomarkers, which 
have enabled a better understanding of RA patho-
biology and also prediction of the onset and timing 
of clinical arthritis.3–5 In this way, symptomatic 
at- risk populations may now be risk stratified for 
future RA development.6 7 Building on this work, 
clinical trials investigating therapeutic intervention 
in at- risk individuals with the aim of RA preven-
tion have been conducted.8 9 Several more are now 
either underway or in preparation; all are targeting 
at- risk populations with the aim of RA preven-
tion. While sharing a common goal, these trials are 
strikingly heterogeneous; different at- risk popula-
tions have been included with different eligibility 
criteria, biomarkers, interventions and outcomes. 
The heterogeneity is a natural consequence of the 
infancy of the field but may present unwelcome 
challenges in interpreting the relevance and validity 
of the findings. As this field grows exponentially, it is 
critical that all future efforts are optimally aligned; 
at- risk individuals are difficult to identify, recruit 
and monitor but provide invaluable opportunity 
for insights into the pathobiology of RA and new 
avenues for prevention that must be maximised.
The current EULAR task force was convened 
with the goal of providing data- driven guidance 
and consensus for use by current and future inves-
tigators in this important area of rheumatology 
research.
METHODS
An international multidisciplinary task force was 
convened with the aim of defining points to consider 
for conducting clinical trials and studies in individ-
uals at risk of RA (co- convened by KM and PE). 
The task force included 13 academic rheumatolo-
gists from Europe and North America with specific 
expertise in this area. There were two project meth-
odologists/epidemiologists (DA and AK). The task 
force also included one health professional (HP), 
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two rheumatologists from the EMerging EULAR NETwork 
(EMEUNET) and two patient representatives from the people 
with arthritis / rheumatism across Europe (PARE) network of 
patient research partners. In developing the points to consider, 
the task force followed the most recent EULAR standardised 
operating procedures for the development of recommenda-
tions.10 The project was fully approved by the EULAR executive 
committee.
At the first meeting (October 2019 in Amsterdam, the Neth-
erlands), the task force discussed the background and focus of 
the project and defined the objectives. Four key questions to 
be addressed by systematic literature reviews (SLRs) were then 
prioritised by a group voting process, supervised by the meth-
odologists. The SLR was performed by the fellow and co- con-
venor (KM) and the allied health professional (AHP) (HJS) 
with support from one of the EMEUNET members (DAR), a 
librarian (Joel Kerry) and a research fellow from Leeds (Andrea 
Di Matteo). Based on the findings of the SLRs, a draft of the 
points to consider and research agenda was prepared by the 
fellow (KM), AHP (HJS), the methodologists (DA and AK) and 
the convenor (PE).
At the second meeting (held in April 2020, by video conference 
due to the COVID-19 pandemic), the SLR results and the draft 
of the points to consider and research agenda were presented 
to the task force. Following group discussions, during and after 
the meeting, the task force agreed on the final consensus state-
ments which encompassed 1 overarching principle, 10 points 
to consider and 1 research agenda. Task force members were 
then asked to anonymously rate the overarching principle and 
points to consider on a scale of 0 (absolutely disagree) to 10 
(absolutely agree) to assess the level of agreement (LoA). The 
research agenda was extensively discussed between members and 
consensus was achieved on the points to be included. Comments 
from external industry stakeholders (Marie Brazil, Francesco De 
Leonardis and Jens Gammeltoft Gerwien) on the final consensus 
statements were proactively elicited and further considered 
during the writing of the manuscript.
RESULTS
Systematic literature review
The task force agreed on the following four questions to be 
addressed by the SLR:
1. In clinical studies involving individuals at risk of RA, which 
populations should be included and what study endpoints 
should be used?
2. In individuals at risk of RA, is there a core set of risk factors 
and how frequently should they be measured?
3. In individuals at risk of RA, does risk- factor- driven interven-
tion alter risk of progression?
4. Is there a benefit in informing individuals at risk of RA 
about their risk of developing RA and offering preventive 
treatment?
It was acknowledged that questions 3 and 4 were focused on 
potential interventions. The task force felt these questions would 
inform the design of clinical trials and studies in this area and 
would be important to include; question 3 would inform which 
potential interventions should be selected by investigators, while 
question 4 would inform recruitment strategies, communication 
approaches and feasibility of future studies.
To address these questions, four separate literature searches 
were conducted (see online supplemental materials for details). 
For each search, the relevant keywords were used in Medline, 
Embase, Pubmed and Central databases. Abstracts from January 
2018 onwards were included. Meta- analyses were included, but 
all other reviews and study protocols were excluded. Manually 
searched articles either from the references of selected manu-
scripts or identified by task force members were also included.
The task force agreed on 1 overarching principle, 10 points to 
consider (table 1) and 1 research agenda. When deciding over-
arching principles, discussion focused on the at- risk populations 
being recruited, data collection, study design and outcomes. 
Consideration was given to principles included in the 10 points 
to consider, to ensure specific guidance included in these points 
was not repeated. It was agreed that only one overarching prin-
ciple should be put forward and this should specify key features, 
which should be collected from all at- risk populations.
Industry stakeholders received the initial draft of the manu-
script and made comments and edits mainly around text 
wording, communication of content and structure. For example, 
statements were clarified with explanatory text where needed. 
The industry stakeholders helped ensuring that the manuscript 
would be relevant and accessible to potential industry partners 
who may be involved in future clinical trials and studies in this 
area. Industry bias was avoided as representatives were chosen to 
provide personal views based on their individual expertise and 
experience only (two in clinical research and trials and one in 
basic and translational science).
Overarching principle
All clinical trials and observational studies in individuals at risk 
of RA should include the epidemiological and demographic 
characteristics of the at-risk population being studied (LoA 10)
The task force recognised the different populations of at- risk 
individuals currently being studied in prospective cohorts inter-
nationally. While individual studies may prioritise the investi-
gation of specific risk factors or a specific intervention in these 
populations, the task force agreed that certain population char-
acteristics should invariably be measured. These are the core 
epidemiological and demographic characteristics of age, sex, 
body mass index (BMI), ethnicity, smoking status and family 
history of RA. Recording these core characteristics enables direct 
comparison and where possible integration of datasets from 
multiple cohorts.
Points to consider
1. For clinical trials or observational studies, individuals at risk of RA 
should be identified according to their clinical presentation. Within 
each clinical presentation, subpopulations should be identified 
based on the presence of specific risk factors (LoA 9.75)
Several different populations of individuals at risk of RA are 
being included in prospective clinical studies and interventional 
trials. The population differences largely reflect the available 
infrastructure, local populations and research interests of the 
various centres involved. Individuals usually present to health-
care professionals because of their clinical symptoms and signs, 
and the evolution of clinical features also reflects the natural 
history of RA development. Therefore, the task force felt it 
appropriate for at- risk populations to be categorised according 
to their clinical presentation. The task force decided against cate-
gorising at- risk populations based on just ‘symptoms’ and ‘signs’, 
as clinical signs (eg, joint tenderness) may be present in the 
absence of clinical synovitis. The term ‘arthralgia’ was avoided 
in categorisation as not all at- risk individuals with musculoskel-
etal (MSK) symptoms have arthralgia, with some presenting 
with non- specific symptoms instead. The task force proposed 
three broad categories, which underpin disease progression: 
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asymptomatic, MSK symptoms without clinical arthritis and 
early clinical arthritis.
Asymptomatic at-risk individuals
Asymptomatic at- risk individuals are typically identified through 
either family relationships or population screening for the pres-
ence of informative autoantibodies.11–13 With these approaches, 
asymptomatic individuals are presumed to exhibit genetic or 
environmental risk factors without clinical symptoms or signs 
of arthritis. The influence of genetic and environmental risk 
factors in asymptomatic individuals who exhibit autoantibodies 
has not been well characterised across prospective cohorts. The 
first- degree relatives (FDRs) of people with RA are a popula-
tion with genetic risk who may be feasibly identified from 
the general population (via the affected RA proband). FDRs 
are currently being studied in multiple research cohorts both 
to understand the pathobiology of RA and to investigate the 
influence of specific risk factors on disease progression in this 
population.14–19 Considering risk factors in FDRs, serum auto-
antibodies and other serum biomarkers have been the best char-
acterised. Serum anti- citrullinated protein antibodies (ACPA) are 
enriched in FDRs20 and associated with arthritis development.17 
Multiple serum cytokines and chemokines are associated with 
ACPA and disease progression in FDRs.21 22 Conversely, omega-3 
fatty acid levels appear to have an inverse relationship with anti- 
cyclic citrullinated protein (anti- CCP) antibodies in those with 
genetic risk.23 24
In addition to FDRs from the general population, specific 
geographical populations also carry a heightened genetic risk 
of RA. Indigenous North Americans (INA), also referred to in 
the research literature as Indigenous Peoples, North American 
Natives, First Nations, First Nations Peoples, North American 
Indians, Aboriginals or Aboriginal peoples, have been the best 
characterised.25 26 Many of these populations exhibit high RA 
prevalence rates of predominantly seropositive, severe disease,27 
familial clustering of cases19 and unfavourable disease outcomes. 
Although likely a significant factor, the increased risk may not be 
solely due to genetics, environmental factors, access to appro-
priate rheumatology care or a combination of these factors are 
also likely to be important. Studies of genetic risk in American 
Indians of Alaska and First Nations Peoples of Central Canada 
have shown that the shared epitope (SE) encoding allele HLA- 
DRB1*1402, which is almost unique to Indigenous Peoples, is 
a particularly important risk factor.28 Non- human leukocyte 
antigen (HLA) genes in these populations also appear to play 
a role.29
Longitudinal studies in FDRs of indigenous populations have 
demonstrated a high prevalence of serum ACPA (~10%) and 
rheumatoid factor (RF) (~15%). Although associated with 
arthritis development, ACPA levels fluctuate over time and not 
uncommonly revert to a seronegative state.30 Also, ACPA IgG 
variable domain glycosylation is a strong predictor of future RA 
development, in such populations.31
Overall, the task force agreed that FDRs, individuals who 
screen positive for ACPA and genetically predisposed indigenous 
populations are important asymptomatic at- risk populations 
that should be studied. Within these populations, serum auto-
antibodies and other serum biomarkers enable identification of 
important subpopulations.
At-risk individuals with MSK symptoms without clinical arthritis
Several different symptomatic at- risk populations without clin-
ical arthritis are being studied. These include ACPA- positive 
individuals with MSK symptoms,7 32 seropositive (ACPA and/or 
RF) individuals with arthralgia33 and individuals with clinically 
suspect arthralgia (CSA).34 35
In these individuals, subpopulations may be defined based on 
serum autoantibodies, serum biomarkers, clinical symptoms and 
Table 1 Overarching principle and points to consider for conducting clinical trials and observational studies in individuals at risk of RA
LoE LoA
Overarching principle





1 For clinical trials or observational studies, individuals at risk of RA should be identified according to their clinical presentation. Within each clinical presentation, 
subpopulations should be identified based on the presence of specific risk factors
5
9.75
2 In clinical trials and observational studies of individuals at risk of RA, the development of clinical arthritis or progression to RA (according to 2010 ACR/EULAR Rheumatoid 
Arthritis Criteria) should be considered as study end- points
2b
9.85
3 The development of subclinical inflammation on US and/or MRI should also be considered as an end- point in at- risk populations without subclinical disease 2b
8.65
4 In at- risk populations with clinical arthritis (ie, PR and UA patients), interventional studies should include disease remission (on/off therapy) as an end- point 1b
9.55
5 In clinical trials or observational studies of individuals at risk of RA, risk factors should be assessed in a population- specific manner, and should include, or be a composite 
of, core and emerging risk factors
5
9.7
6 Risk factors should be assessed at baseline and repeated assessment considered according to the specifics of the study population and intervention 5
9.75
7 Clinical trials should evaluate the ability of a specific intervention to modify the risk factor itself (as well as the risk of progression to RA) 5
9.65
8 In individuals at high risk of RA (eg, with early clinical synovitis), drug intervention should alter progression to RA or the outcome of RA therapy 1b
9.5
9 In clinical trials and observational studies, individuals should be informed about their risk of developing RA using an approach tailored to the individual participants 5
9.5
10 Individuals should be informed about their risk of progression to RA, as this may modify their decision to participate, or not, in clinical trials and observational studies 2b
9.85
LoA; mean LoA of taskforce members. 1a systematic review of randomised controlled trials (RCTs); 1b, individual RCT; 2a, systematic review of cohort studies; 2b, individual cohort study (including 
low quality RCT); 3a, systematic review of case–control studies; 3b, individual case–control study; 4, case series (and poor- quality cohort and case–control studies); 5, expert opinion without 
explicit critical appraisal, or based on physiology, bench research or first principles.
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; LoA, level of agreement; LoE, level of evidence; MRI, magnetic resonance imaging; PR, palindromic 
rheumatism; RA, rheumatoid arthritis; UA, undifferentiated arthritis; US, ultrasound.
 on A









is: first published as 10.1136/annrheum





4 Mankia K, et al. Ann Rheum Dis 2021;0:1–13. doi:10.1136/annrheumdis-2021-220884
Recommendation
subclinical inflammation on imaging. In ACPA- positive individ-
uals with MSK symptoms, a high anti- CCP level and the presence 
of RF are strongly associated with arthritis development.7 A high 
ACPA level is also associated with disease progression in ACPA- 
positive individuals without arthritis, but less well- defined clinical 
symptoms.36 37 In patients with seropositive arthralgia, the pres-
ence of anti- CCP antibodies, a high level of anti- CCP antibodies, 
the extent of the ACPA repertoire and dual positivity to anti- CCP 
and RF are all associated with arthritis development.6 33 38 39 ACPA 
and RF positivity are also associated with arthritis development in 
individuals with CSA.35 40 Anti- carbamylated antibodies have also 
been shown to be associated with arthritis development in patients 
with seropositive arthralgia.41 Serum and cellular biomarkers (T 
cell subsets) have predictive value in ACPA- positive individuals 
with MSK symptoms42 and seropositive arthralgia.43 44 The pres-
ence of certain clinical symptoms such as small joint tenderness and 
early morning stiffness are relevant for risk stratification in ACPA- 
positive individuals with MSK symptoms and patients with sero-
positive arthralgia.6 7 In patients with CSA, difficulty making a fist 
and a positive ‘squeeze test’ are associated with subclinical inflam-
mation on MRI particularly tenosynovitis45 46 and is predictive of 
arthritis development.45 A set of clinical features in individuals at 
risk of RA were defined by a recent EULAR task force.34
In ACPA- positive individuals with MSK symptoms, patients 
with seropositive arthralgia and patients with CSA, subclinical 
inflammation on imaging has been characterised on ultrasound 
(US) and MRI. Intra- articular inflammation (grey scale and 
power Doppler signal) is the most relevant on US,47 48 whereas 
tenosynovitis is the most specific and predictive feature for 
arthritis development on MRI.49 50
The task force agreed that serum autoantibodies (especially 
ACPA), serum and cellular biomarkers, clinical features and 
subclinical inflammation on imaging should all be used to 
characterise subpopulations in symptomatic at- risk individuals 
without clinical arthritis.
At-risk individuals with early clinical arthritis
Two important populations with early clinical arthritis who are 
at risk of progression to RA are patients with undifferentiated 
arthritis (UA) and palindromic rheumatism (PR). Both have been 
studied extensively in prospective cohorts. For both conditions, 
clinically relevant subpopulations may be defined based on the 
presence of serum autoantibodies,51–54 serum biomarkers, clin-
ical features54 and subclinical inflammation on imaging.55–57 In 
both PR and UA, these factors may be used for risk stratification 
(discussed below).
2. In longitudinal studies of individuals at risk of RA, the 
development of clinically evident arthritis, or progression to RA 
(according to 2010 ACR/EULAR Rheumatoid Arthritis Criteria), 
should be considered as study end-points (LoA 9.85)
Most longitudinal studies in at- risk populations have been 
performed in cohorts of individuals who have MSK symptoms 
without clinical arthritis (as described in point 1). The develop-
ment of clinically evident arthritis is the most frequently studied 
primary end- point in longitudinal studies in ACPA- positive indi-
viduals with MSK symptoms, patients with seropositive arthralgia 
and patients with CSA. In many cases, individuals who develop 
clinical arthritis will also meet ACR/EULAR classification criteria 
for RA.58 This criterion is often included as a separate secondary 
end- point in studies. Investigators of a large Mexican longitudinal 
cohort study of relatives of RA probands (including FDRs) defined 
the development of clinical inflammatory arthritis (IA) as the 
primary end- point17 as have others.59 Longitudinal studies of INA 
have used development of RA as the primary end- point.30 60
Longitudinal studies of at- risk populations with clinical arthritis 
(ie, UA and PR) have specified the development of RA (either 
2010 ACR/EULAR Criteria or previously accepted criteria) as the 
primary end- point. For PR, all such longitudinal studies have used 
the 1987 (or older) criteria due to age of the studies.51–53 61–65 In 
these studies, the primary end- point represents a clear transition 
from a relapsing–remitting phenotype to a persistent arthritis. In 
studies of patients with UA, the population is described as having 
undifferentiated or unclassified arthritis or early IA not meeting 
classification criteria for RA.66–76 In each case, the definition of 
UA is based on having clinical arthritis but not meeting the spec-
ified classification criteria for RA. Therefore, the RA classifica-
tion criteria used are critical to the interpretation of the findings. 
The task force acknowledged that many of the patients with UA 
included in studies, which have not used the most recent classi-
fication criteria, are likely to have met the updated 2010 criteria, 
which is more sensitive for early disease.
3. The development of subclinical inflammation on US and/or MRI 
should also be considered as an end-point in at-risk populations 
without subclinical or clinical disease (LoA 8.65)
In at- risk populations without clinical or subclinical joint disease, 
the development of pathological subclinical inflammation on 
imaging is a significant step as it represents a transition from 
systemic autoimmunity to local articular inflammation, and is 
associated with imminent clinical arthritis. To reflect this, some 
longitudinal cohort studies stipulate the development of imaging- 
detected synovitis as the primary study end- point.77 Subclinical 
synovitis on US also influences clinical decision- making in at- risk 
individuals with MSK symptoms.78 The task force, therefore, felt 
it appropriate that the development of subclinical inflammation 
on imaging should be considered as an end- point distinct from 
the development of clinical arthritis (see table 2 for definitions of 
arthritis). The most appropriate imaging modality and protocol 
to use for detection of subclinical inflammation in at- risk popu-
lations are a subject for future research and were beyond the 
scope of the current task force.
4. In at-risk populations with clinical arthritis (ie, patients with PR 
and UA), interventional studies should include disease remission 
(on/off therapy) as an end-point (LoA 9.55)
Several interventional studies have been performed in patients 
with UA. Some have specified disease remission as the primary 
study end- point.68 79 80 In addition, others have included disease 
remission as a secondary end- point,81–84 with the primary 
end- point instead being the development of classifiable RA. 
Of those studies stipulating disease remission as an end- point, 
the majority tested short- term induction therapy, that is, the 
ability to achieve drug- free remission (DFR). In the PROb-
able rheumatoid arthritis: Methotrexate vs Placebo Treatment 
(PROMPT) trial, van Dongen et al investigated 12 months of 
Table 2 Definitions of arthritis
Asymptomatic
The absence of arthralgia or other musculoskeletal 
symptoms
Symptoms not exclusively musculoskeletal, such as 
fatigue may be present
Subclinical inflammation on 
imaging
The presence of signs of joint inflammation on high- 
resolution imaging in the absence of clinical arthritis
Clinical arthritis The presence of inflammatory joint swelling on clinical 
examination
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induction therapy with methotrexate (MTX) in patients with 
UA and stipulated DFR at 30- month follow- up as a study end- 
point. There was no significant difference in DFR rates in the 
MTX and placebo arms.82 However, in a subanalysis of high- 
risk patients only (Leiden prediction score ≥8), DFR at 30 
months was achieved in 36% of the MTX arm compared with 
0% in the placebo arm (p=0.027), although in a total of only 
22 patients.81 In the Stop Arthritis Very Early (SAVE) trial, 
the primary end- point was disease remission at 12 weeks and 
15 weeks after a single intramuscular injection of methylpred-
nisolone or placebo. DFR was achieved by 32/198 (16.2%) 
of the treatment group and 33/185 (17.8%) of the placebo 
group (p=0.68).79 In a recent observational study, data were 
used from the Induction therapy with MTX and prednisolone 
in Rheumatoid Or Very Early arthritic Disease (IMPROVED) 
study to specifically investigate predictors of DFR at 1 year in 
a subgroup of patients with UA who achieved remission and 
tapered all therapy at 8 months, according to a predefined 
protocol.80 In a recent small study of infliximab (IFX; given at 
week 0, week 2, week 6, week 14 and week 22) versus placebo 
in patients with ACPA- positive UA, DFR (according to DAS28 
CRP) at 1 year was observed in 50% of the IFX group versus 
21.4% of the placebo group.83
In contrast to the above- mentioned studies, two trials 
have used disease remission while still on therapy as an 
end- point.68 84 The first was a trial of IFX in patients with 
poor- prognosis UA who relapsed after a single corticosteroid 
injection, and the second a study of MTX compared with 
placebo. There was no difference in remission rates in the IFX 
study, whereas in the more recent MTX study, the proportion 
of patients who achieved Boolean remission after 1 year was 
greater in the MTX group compared with the placebo group.84
In a recent interventional study performed in a PR cohort, 
a predefined disease modifying anti- rheuamtic drug (DMARD) 
escalation protocol was used to bring flares under control with 
the aim of achieving disease remission.85 Complete or partial 
remission was achieved in 76/106 (82.6%) of patients, while 
16.3% of patients were able to discontinue medications and 
achieve DFR. Disease remission (defined as the absence of flares 
for ≥1 month) on therapy was also the primary end- point in a 
study of rituximab (RTX) in PR.86 All of the 33 patients with 
seropositive PR in this study eventually achieved remission, 
although some required four cycles of RTX to do so. Neither of 
these studies were controlled trials.
5. In clinical trials or observational studies of individuals at risk of 
RA, risk factors should be assessed in a population-specific manner. 
Risk factors should include, or be a composite of, core and emerging 
risk factors (LoA 9.7)
Risk factors for the development of RA have been investi-
gated using both large retrospective case–control studies and 
prospective cohort studies in predefined at- risk populations. 
The advantage of the former is the availability of large data-
sets from national and international registries, which allow the 
influence of specific genetic or environmental risk factors in the 
background population to be accurately quantified. However, to 
investigate the influence of specific risk factors in at- risk popu-
lations (as opposed to the general population), as well as the 
effects of risk factors that operate in a stage- specific manner, 
prospective cohort studies have proven most valuable.
Several different risk factors have been investigated in 
prospective cohort studies in well- defined at- risk populations. 
The task force agreed that risk factors are population specific, 
for example, symptom complexes and imaging are only rele-
vant in at- risk populations who have symptoms. Therefore, risk 
factors should to be assessed according to the at- risk population, 
which is being included in a particular study or trial. Within each 
population, some risk factors have a strong evidence base, while 
others have a more limited evidence base. It was, therefore, felt 
that ‘core’ and ‘emerging’ risk factors may be defined based on 
the current evidence base. The task force agreed that core risk 
factors should, where feasible, always be assessed in a clinical 
trial or observational study (table 3).
Asymptomatic at-risk individuals
Studies in large prospective cohorts of individuals with genetic 
risk factors for RA or identified in population screening have 
demonstrated that the additional presence of ACPA and other 
autoantibodies are significant risk factors for arthritis develop-
ment. Anti- CCP- positive relatives (mainly FDRs) of RA probands 
are at much higher risk of developing RA compared with their 
seronegative counterparts (positive predictive value (PPV) of 
64% for RA development at 5 years in CCP+/RF + relatives).17 
Similarly, 30% of anti- CCP+/RF + relatives of INA developed 
RA after a median of 3- year follow- up.30 Before the availability 
of ACPA testing, a seminal study of over 2000 healthy INA moni-
tored biannually for up to 19 years revealed a highly significant 
association between RF level and RA development (p<0.001, 
controlling for age and sex).60
Genotype also confers additional risk of ACPA and RA in 
FDRs of INA populations. The combination of HLA- DR SE 
and the non- SE allele DRB1*0901 is associated with ACPA and 
earlier age of RA onset in these FDRs.87 IgG ACPA glycosylation 
also appears to be strongly predictive of the future development 
of RA in INA FDRs.31
The core and emerging risk factors, which should be assessed 
in this population, are summarised in table 3.
At-risk individuals with MSK symptoms but without clinical arthritis
Several risk factors for the development of clinical arthritis and 
RA have been identified in ACPA- positive individuals with MSK 
symptoms, patients with seropositive arthralgia and patients 
with CSA. Autoantibodies (especially ACPA), clinical symptoms 
and imaging markers have the strongest evidence base.
The importance of ACPA status has been confirmed in various 
international cohorts, including a UK ACPA+ cohort with new 
Table 3 Core and emerging risk factors for arthritis according to 
different at- risk populations
At- risk 
population Core risk factors for arthritis











Serum autoantibody profiling (including 
ACPA/RF)
Subclinical inflammation on imaging (US 
and MRI)
Clinical symptoms (EMS duration, joint 
tenderness and symptom duration)






Genetic markers: serum autoantibody 
profiling (including ACPA/RF)
Subclinical inflammation on imaging (US 
and MRI)
Clinical symptoms (EMS duration, joint 
tenderness and symptom duration)




ACPA, anti- citrullinated protein antibodies; EMS, early morning stiffness; MSK, 
musculoskeletal; RF, rheumatoid factor; US, ultrasound.
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non- specific MSK symptoms,7 a Dutch seropositive (CCP+/
RF+) arthralgia cohort33 38 and a Dutch CSA cohort.40 The 
heightened risk conferred by high- tire ACPA is reflected in 
the highest weighting given to this risk factor in two clinical 
prediction rules for arthritis development.6 7 Anti- carbamylated 
protein (anti- CarP) antibodies also appear to confer additional 
risk of arthritis development in ACPA/RF + at- risk individuals, 
independent of ACPA status.41 However, the level of risk does 
not appear to be as pronounced as that related to ACPA.
Certain clinical features are associated with an increased risk 
of arthritis development. Of these, prolonged early morning 
stiffness (EMS) duration is a cardinal symptom. Prolonged EMS 
duration is an important risk factor for arthritis in ACPA+ indi-
viduals with MSK symptoms (EMS >30 min)7 and patients with 
seropositive arthralgia (EMS >60 mins),6 and has been included 
in clinical prediction rules. EMS is also one of the components 
included in the agreed definition of CSA34 and is associated with 
arthritis development in unselected patients presenting with 
arthralgia.88 Joint tenderness (especially of the small joints) was 
also associated with arthritis development in ACPA+ individ-
uals with MSK symptoms7 36 in two cohorts. Other symptom 
complexes were associated with progression to arthritis in sero-
positive arthralgia—duration of symptoms less than 1 year, inter-
mittent symptoms and history of joint swelling.6 These symptoms 
were not prognostic in the UK ACPA+ cohort, perhaps because 
all individuals had new- onset symptoms and patients with PR 
were specifically excluded.
Abnormalities on high- sensitivity US and MRI (and positron 
emission tomography in one study89) also signify an increased 
risk for arthritis development in at- risk individuals. These abnor-
malities reflect the presence of intra- articular and extracap-
sular subclinical inflammation, in at- risk individuals who have 
symptoms without clinically evident arthritis. Several studies 
have identified the presence of subclinical US synovitis (power 
Doppler and grey scale) as a risk factor for arthritis development 
both at joint and patient level.47 48 90 91 Recent data suggest US 
tenosynovitis is associated with arthritis development in ACPA+ 
individuals with non- specific MSK symptoms and no subclin-
ical synovitis on baseline US.77 92 In those with symptoms, the 
development of US synovitis appears to be a relatively late event, 
reflecting imminent clinical arthritis,93 especially as more joints 
become involved.94
MRI studies in ACPA+ individuals with MSK symptoms and 
patients with CSA have identified tenosynovitis as both the most 
prevalent abnormality and the strongest MRI risk factor for 
arthritis development.35 50 95 Tenosynovitis was the only MRI 
abnormality associated with arthritis progression at patient level 
in a study of 98 ACPA+ individuals with MSK symptoms (HR 
4.02 (1.91–8.44), p=0.002).95 Similarly, tenosynovitis was the 
only MRI risk factor independently associated with arthritis 
development in a prospective study of 150 patients with CSA 
(HR 8.39 (3.38–20.81), p<0.001). There is also an increased 
prevalence of hand interosseous tendon inflammation in ACPA+ 
individuals with MSK symptoms.96 These studies highlight the 
importance of extracapsular inflammation (which MRI is partic-
ularly sensitive for) as a risk factor for disease progression.
Other clinical, cellular and serological risk factors for arthritis 
development have also been identified in this population, 
although current evidence for these factors is based largely on 
single unvalidated studies. Elevated BMI has been associated 
with arthritis development in some patients with seropositive 
arthralgia97 and ACPA+ at- risk individuals (some FDRs and 
some with MSK symptoms).98 Studies in the Dutch seroposi-
tive arthralgia cohort have shown that the number of peripheral 
blood B cell receptor clones,99 serum apolipoprotein A1100 and 
serum 14-3- 3n levels101 are all associated with arthritis develop-
ment. Loss of bone mineral density was associated with arthritis 
development in a prospective study in patients with CSA.102 
Peripheral blood T cell subsets were also associated with arthritis 
development in ACPA+ at- risk individuals.42 The peripheral 
blood B cell signature103 and type I interferon signature104 have 
also been shown to be predictive of arthritis development in 
patients with seropositive arthralgia.
Early clinical arthritis
Clinical features, imaging findings and autoantibody profile 
are also important risk factors for the development of RA in 
patients classified as having UA. These data are largely based 
on prospective analyses of UA cohorts, with patients with early 
arthritis included on the basis of failure to meet now outdated 
versions of RA classification criteria. As such, it is likely that a 
significant proportion of these patients would now, based on 
current criteria,58 classify as early RA. Several risk prediction 
tools, combining clinical features, autoantibodies and/or imaging 
risk factors, have been proposed in UA cohorts.66 69–71 73 105–107 
Many of the risk factors are the same as those described above 
for individuals with MSK symptoms without clinical arthritis; 
prolonged EMS duration,69 105 106 ACPA and/or RF,66 69 71 73 105 106 
and power Doppler (PD) signal on US105 have all been shown 
to predict progression of UA to RA. However, elevated CRP/
ESR,69 105 longer disease duration,73 105 greater number of 
swollen and/or tender joints69 73 and radiographic erosions69 70 
are risk factors for progression specific to patients with early 
clinically apparent arthritis. Autoantibody profile (ACPA and 
RF) and flares involving the hands and wrists are also risk factors 
for RA development in patients with PR.51 52
Subclinical inflammation on US and MRI has been identified 
as a risk factor for RA development in several UA cohorts.108–113 
The presence of US synovitis (gray- scale (GS) and/or PD) 
is predictive of progression from early UA to RA.110–112 114 
However, tenosynovitis in the hands and feet113 on US and MRI 
also appears to be associated with disease progression.109 112 Of 
the studies investigating the role of autoantibody profiling in UA, 
ACPA status and level (high level most predictive) are the most 
consistently predictive of disease progression.67 72 74
There has been considerable interest in the putative role of 
mucosal inflammation and dysbiosis in initiating and driving 
disease progression in at- risk individuals.15 115–119 The potential 
importance of this was recognised by the task force. Although 
limited data were identified reporting these as specific risk 
factors for arthritis development,120 the task force felt that these 
factors should be considered in future studies and clinical trials.
Considering the available data, the task force proposed that 
specific core and emerging risk factors should be assessed in 
symptomatic at- risk populations, that is, at- risk individuals with 
symptoms (but no clinical synovitis) and individuals with early 
clinical arthritis (table 3).
6. Risk factors should be assessed at baseline and repeated 
assessment considered according to the specifics of the study 
population and intervention (LoA 9.75)
The majority of studies investigating risk factors in prospective 
at- risk cohorts have taken only a single baseline measurement 
of the risk factor(s). While this provides valuable information 
on the overall influence of risk factors on the development of 
arthritis, a single measurement cannot address whether and to 
what extent risk factors change over time, nor the relationship 
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between different risk factors over time. For example, some risk 
factors may be more relevant in the asymptomatic at- risk phase, 
while others may become more relevant in symptomatic individ-
uals when the onset of clinical arthritis is imminent.
In line with this, recent data suggest the prevalence and overall 
burden of subclinical joint inflammation on US imaging increases 
over sequential assessments prior to arthritis development in 
ACPA+ individuals with MSK symptoms.93 94 This suggests that 
US subclinical inflammation is most relevant in those with immi-
nent arthritis. There is a paucity of longitudinal, repeated assess-
ments of other risk factors, particularly the evolution of clinical 
symptoms or cellular/serological markers. Investigators may seek 
to understand the influence of interventions on risk factors (ie, 
surrogates of disease progression), as well as arthritis develop-
ment. An understanding of the stability of risk factors will be 
critical to designing such studies. The task force felt that this was 
an area which should be prioritised in future clinical trials and 
longitudinal studies.
7. Clinical trials should evaluate the ability of a specific intervention 
to modify the risk factor itself, as well as the risk of progression to 
RA (LoA 9.65)
Clinical trials in individuals at risk of RA have primarily focused 
on the prevention of progression to clinical arthritis or RA. 
Given increasing evidence for the role of specific risk factors in 
driving disease progression (as detailed above), the task force 
felt that evaluation of the ability of interventions to modify 
an individual’s underlying risk factors should be prioritised in 
future study designs. This would be important for two reasons: 
first, to better understand the relative influence of specific risk 
factors on disease progression and second, it would represent an 
important step towards personalising different types of preven-
tive intervention (eg, pharmacotherapies, lifestyle modifications 
or a combination) by understanding their suitability to target 
specific risk factors, which may be enriched in different at- risk 
populations.
Published studies suggest modification of risk factors in this 
way is feasible; improvement in RA- autoantibody levels has been 
reported in interventional trials in both patients with seroposi-
tive arthralgia and patients with UA.8 121 In the Abatacept study 
to determine the effectiveness in preventing the development of 
rheumatoid arthritis in patients with Undifferentiated inflamma-
tory arthritis and to evaluate safety and tolerability (ADJUST) 
trial, induction therapy with abatacept (ABT) in patients with 
UA was associated with a reduction in anti- CCP level. MRI oste-
itis scores also improved with ABT therapy and this benefit was 
sustained 6 months after treatment withdrawal.121
8. In individuals at high risk of RA (eg, with early clinical synovitis), 
drug intervention should alter progression to RA or the outcome of 
RA therapy (LoA 9.5)
Clinical trials have shown that in patients with UA, drug inter-
vention can reduce or delay progression to RA and improve the 
outcome of therapy.81 82 84 121–123 There is particularly strong 
evidence for a beneficial effect of MTX in UA.81 82 84 The Dutch 
PROMPT study showed a delay in development of RA when MTX 
and placebo (12 months induction treatment) were compared 
in unselected patients with UA, although there was no overall 
difference in progression to RA at 30 months.82 There was also 
no difference in disease remission rate at 30 months. However, 
when considering only the patients with anti- CCP- positive UA, 
93% of the placebo arm progressed to RA compared with only 
67% of the MTX arm (p<0.001) indicating a preventive effect. 
Furthermore, in a subsequent analysis restricted to 22 patients 
with ‘high- risk’ UA, a clear benefit of MTX was demonstrated; 
6/11 (55%) of patients with high- risk UA developed RA in the 
MTX arm compared with 11/11 (100%) in the placebo arm, 
although in small numbers of patients.81 Of the patients that 
developed RA in the MTX arm, this was delayed compared with 
placebo (median 22.5 months vs 3 months; p<0.001) and DFR 
was achieved by 4/11 (36%) in the MTX arm compared with 
0/11 (0%) in the placebo arm (p=0.031). A separate study also 
showed a beneficial effect of MTX in patients with anti- CCP- 
positive UA; after 12 months’ therapy, only 17.2% of patients in 
the MTX arm progressed to RA compared with 78.9% of those 
in the placebo arm (p<0.001).84 Boolean remission was achieved 
in 46.4% of the MTX arm compared with 17.6% of the placebo 
group (p=0.057).
Six months of ABT therapy in patients with anti- CCP- positive 
UA also showed beneficial effects on radiographic and MRI 
disease progression and anti- CCP levels at 1 year compared with 
placebo.121 Fewer patients in the ABT arm progressed to RA, but 
statistical significance was not reached in this small study. An 
important caveat, as with many of the UA studies, is that many of 
the included patients would now meet the updated classification 
criteria for RA58 and would no longer be considered eligible for 
such studies.
Trials investigating the benefits of induction therapy with corti-
costeroids in altering disease progression in UA have produced 
less impressive results.79 124 One such trial investigated the effect 
of three 80 mg intramuscular injections of methylprednisolone 
compared with placebo on disease progression (judged as the 
need to start DMARDs) and development of RA at 1 year. Corti-
costeroids delayed disease progression (76% vs 61% referred to 
start DMARDs at 6 months; OR 2.11, 95% CI 1.16 to 3.75, 
p=0.015) but did not prevent the development of RA.124 Simi-
larly, in the SAVE trial, a single 120 mg intramuscular injection 
of methylprednisolone produced similar disease remission rates 
compared with placebo at 1 year (16.2% vs 17.8% in methyl-
prednisolone vs placebo) and similar progression to RA (45.1% 
in steroid arm vs 50.1% placebo arm).79
Studies investigating the use of tumour necrosis factor (TNF) 
- alpha inhibitors as induction therapy in UA have been limited; 
those reported have failed to show an impact in altering progres-
sion to RA.68 83 In patients with high- risk UA, only 20% of 
IFX- treated patients achieved remission at 6 months, compared 
with 14% of placebo. All patients in the IFX arm developed RA 
at 1 year.68 The majority of patients with IFX- treated UA also 
progressed to RA in a recent study (73% of IFX arm compared 
with 67% of placebo arm).83
The limited available studies in patients with PR suggest drug 
intervention may have a role in altering progression to RA in 
this population, although the evidence is much weaker than 
for UA, as appropriately designed clinical trials have not been 
performed. Antimalarial therapy appeared to delay the develop-
ment of RA (162 months vs 56 months, p=0.03) in a retrospec-
tive cohort study, although there was no difference in overall 
rates of progression to RA.61 Relatively low progression rates 
to RA were also reported in cohorts of patients with PR treated 
with DMARDs, although these were not controlled studies, 
which limits their interpretation.65 85
Considering the available data, the task force felt drug inter-
vention should be considered in patients with UA with the aim of 
reducing disease progression and improving RA outcomes. The 
benefit of drug intervention in PR is less clear at present although 
antimalarials may be beneficial and warrant further study. 
There is no current evidence for the use of drug intervention in 
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delaying disease progression in at- risk individuals without clin-
ical arthritis.
9. In clinical trials and observational studies, individuals should 
be informed about their risk of developing RA using an approach 
tailored to the individual participants (LoA 9.5)
The task force felt it important that individuals at risk of RA 
are optimally engaged with strategies to identify their risk and/
or potentially reduce their risk through intervention. Thematic 
synthesis of qualitative data and quantitative data from preven-
tive intervention studies informed points to consider 9 and 10.
Only a few studies have explored the perspectives of indi-
viduals at risk of RA regarding risk prediction and RA preven-
tion. There are two studies in people with MSK symptoms but 
without clinical arthritis (including arthralgia)125 126 and five in 
FDRs.127–132 Additionally, there is one study in people who have 
been diagnosed with RA133 and another includes views from 
members of the public.134
Individuals with arthralgia (94%) report that they have bene-
fited from being informed about their risk of developing RA.126 
FDRs are aware of their susceptibility to RA but at the same time 
unsure of the extent of their risk.128 FDRs have raised concern 
that knowing their absolute risk would increase their anxiety and 
potentially affect decisions about their future and they would 
need additional support to understand the risk and cope with 
the emotional impact of this information.128 A randomised 
controlled trial (RCT) comparing a web- based tool (Personalized 
Risk Estimator for Rheumatoid Arthritis) with standard, non- 
personalised RA education showed that the tool may help such 
individuals to better calculate disease risk.131
Identifying personal risk factors is important for FDRs, partic-
ularly when it comes to addressing modifiable ones such as 
diet.129 An RCT conducted in FDRs without RA concluded that 
personalised medicine approaches increase motivation for those 
at risk to improve behaviours that reduce the risk of developing 
RA.130
An individual tailored approach for communication has been 
acknowledged by patients with RA; they have highlighted that 
sharing risk information with relatives may cause negative 
emotions, particularly because of the negative impact on quality 
of life that RA has133; as such, they would prefer to choose with 
whom the information is communicated.
The task force agreed that it was important for individ-
uals participating in clinical trials and observational studies 
to understand their personal risk of developing RA. Commu-
nication should be tailored to the individual and additional 
support should be considered. This is particularly important for 
promoting participation and engagement in prevention studies.
10. An individual’s knowledge about their risk of progression to RA 
may inform their decision to participate, or not, in clinical trials and 
observational studies (LoA 9.85)
The variable accuracy of predictive models in identifying an indi-
vidual’s risk of developing RA has been raised by FDRs128 and 
people with CSA, highlighting difficulties in interpreting prog-
nostic information given to them.125 People with CSA preferred 
to have information on the origin of their symptoms,125 thus 
exploring illness perceptions to guide treatment decisions, rather 
than risk percentages. How individuals receive information 
about their risk may, therefore, contribute to their decision to 
participate in interventional studies or not.
A recent study included at- risk individuals, defined on the 
basis of ACPA/RF positivity. In that study, those with arthralgia 
(≥one peripheral joint) were more likely to have had an auto-
antibody test to help identify the cause of their symptoms; in 
contrast, asymptomatic individuals were more likely to have had 
a test to contribute to research. Many symptomatic individuals 
expressed willingness to undergo additional predictive testing, 
including an assessment of the synovium by biopsy, if that would 
help further refine risk estimation. Asymptomatic individuals 
were less likely to consider further predictive testing.
Importantly, both groups highlighted the need for tailored, 
patient- understandable information to be delivered by an HP.
Prevention intervention studies are typically grouped into 
those that involve lifestyle and/or behaviour modification or 
those that involve taking medication. At- risk individuals with 
symptoms are more likely to consider both interventions.126 
This contrasts with FDRs who would prefer to wait until 
symptoms developed before considering drug interventions.129 
An understanding of personal risk is more likely to improve 
RA- risk- related behaviours such as dental hygiene and dietary 
change.129 130 However, preventive treatment offering the largest 
risk reduction is not necessarily the priority for asymptomatic 
FDRs.132
The task force acknowledged that level of baseline risk typi-
cally informs study protocols for preventive interventions, either 
lifestyle/behaviour modification or pharmacotherapy. Hence, 
supporting individuals at risk of RA to understand their personal 
risk factors and overall level of risk is likely to help inform their 
decision to participate, or not, in clinical trials and observational 
studies.
Figure 1 A summary of assessments and end- points which should be collected in clinical trials and observational studies of individuals at risk of 
RA, according to the at- risk population. MSK, musculoskeletal; RA, rheumatoid arthritis.
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The task force acknowledged that points 9 and 10 follow 
the same theme, but convey separate messages, which justifies 
having two separate points. Point 9 refers to the approach to be 
used to inform participants about their risk. This point is centred 
on communication strategies, which should be considered when 
planning clinical trials and studies in at- risk populations. Point 
10 refers to factors which may influence participation in trials 
and clinical studies. This point explores reasons why participa-
tion in studies may be limited and how it could be improved.
CONCLUSION
The goal of this EULAR task force was to provide the first expert 
consensus and guidance on the conduct of clinical trials and 
observational studies in individuals at risk of RA. These studies 
represent a new and evolving area in rheumatology research and 
clinical practice. Although much of the guidance is based on 
robust data from multiple studies, some is based on low levels 
of evidence and expert opinion. Therefore, guidance state-
ments have been formulated as ‘points to consider’ rather than 
recommendations (table 1). Validation of the points to consider 
was beyond the scope of the task force but could be consid-
ered in a larger independent group of stakeholders in future. 
We acknowledge that guidance could not be provided in some 
specific areas, for example, at- risk individuals who develop non- 
articular diseases (eg, eye disease and lung disease) in the absence 
of arthritis. This is due to a lack of published evidence in these 
areas.
Several clinical trials in individuals at risk of RA are in prog-
ress and there is a growing interest from multiple stakeholders, 
including rheumatologists, academics, policy- makers, the phar-
maceutical industry and, most importantly, patients. In many 
ways, these studies represent uncharted territory in rheuma-
tology; aiming to prevent arthritis those with risk factors, rather 
than the conventional paradigm of suppressing the disease once 
it is clinically established. As such, there are many important 
differences and unknowns. The goal of the task force was to 
address these uncertainties by providing expert consensus and 
data- driven guidance where available to help optimise the 
conduct of work in this area.
The overarching principle and 10 points to consider set out 
a broad framework, which covers the key areas for conducting 
clinical trials and studies in at- risk individuals. The areas 
included were those prioritised by the task force. This includes 
the different types of at- risk populations, and how they may 
be distinguished based on clinical presentation, for trials and 
studies. For each of these populations, guidance on appropriate 
study end- points and trial outcomes, and the core and emerging 
Box 1 Continued
lung, gut and synovium) in studies of individuals at risk for 
RA?
 ► What is the optimum approach (including psychological 
support/counselling) for conveying risk of RA to these 
individuals?
 ► How do at- risk individuals assess risk versus benefit in 
deciding on participation in either lifestyle or drug prevention 
studies?
 ► Which risk factors do patients consider are high risk for 
developing RA?
 ► Should risk prevention strategies be tailored for differing 
cultural dimensions?
Box 1 Research agenda
The task force agreed that future research should address the 
following key questions:
 ► Should individuals with mucosal inflammation/dysbiosis 
(periodontal, lung or gut) with or without genetic 
predisposition or serum autoantibodies be included as an 
at- risk group?
 ► Are non- musculoskeletal symptoms (eg, stress- related 
symptoms and fatigue) prevalent in individuals at risk of 
developing rheumatoid arthritis (RA)?
 ► Which surrogate biomarkers should be used as end- points 
in pilot/early phase interventional studies? And in which 
populations?
 – Improvement of subclinical inflammation on ultrasound 
(US)/MRI in symptomatic individuals?
 – Improvement of clinical features (eg, early morning 
stiffness duration and small joint tenderness) in 
symptomatic individuals?
 – Improvement of mucosal inflammation with or without 
dysbiosis in seropositive asymptomatic individuals?
 – Development of autoimmunity in seronegative individuals 
with genetic risk (including first- degree relatives)?
 – Improvements in patient reported outcomes (PROs) 
for symptomatic patients? And which patient reported 
outcomes should be used as end- points?
 – Biomarkers of inflammation/autoimmunity (emerging).
 ► Can at- risk populations, from the background population, be 
cost- effectively identified, recruited and given preventative 
treatment based solely on demographics (age, sex and 
smoking status)?
 ► Does subclinical inflammation on imaging represent a 
relevant endpoint (with distinct predictors)?
 ► Do the risk factors that drive RA autoimmunity and disease 
progression vary according to the ethnicity or geography of 
the population?
 ► Which biomarkers/risk factors change as individuals progress 
to inflammatory arthritis?
 ► In individuals at risk of RA, what is the sequence and 
timescale of the changes in biomarkers/risk factors?
 ► How frequently should we reassess an individual’s risk and is 
this subpopulation dependent?
 ► Which biological pathways are linked with progression to RA?
 ► Should interventions be personalised to an individual’s 
risk factors, for example, smoking cessation, treatment of 
periodontitis and weight loss?
 ► In those at high risk, should multimodal intervention 
be considered according to risk factors, for example, 
immunomodulation combined with periodontal therapy/
smoking cessation/weight loss as appropriate?
 ► Does reduction in one or more risk factors reduce the 
likelihood of progression?
 ► Can the quantification of an individual’s risk be improved, 
and risk scores validated?
 ► Are interventional studies in at- risk individuals cost effective?
 ► Should studies assess the long- term impacts of pre- arthritis 
interventions, including impacts on the RA phenotype (eg, 
severity, treatment response, DFR, etc), if it develops?
 ► Should we develop standardised methodologies to optimise 
acquisition and comparability of potentially relevant clinical 
and epidemiological data and biospecimens (eg, blood, oral, 
Continued
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risk factors, which should be assessed, are provided (table 3, 
figure 1). Considerations for optimising participation in these 
studies and informing at- risk individuals about their level of risk 
are also included. Finally, a research agenda, agreed by the task 
force, has also been proposed (box 1).
These statements should help harmonise the datasets produced 
by future studies and facilitate collaboration in this important 
area. They should also improve the validity of individual trials 
and studies, optimising outputs from hard to recruit populations, 
which often require unique patient cohorts and infrastructure. It 
is hoped that this guidance will help galvanise future collabora-
tive efforts in studies of at- risk individuals and RA prevention.
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